Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Roxus, a prescription nasal spray for erectile dysfunction, is now available in the US through men's health telemedicine platform Mavrox. It delivers vardenafil — a well-known ED drug — directly through the nose, reaching peak blood levels in about 10 minutes, far faster than the 45–60 minutes typical of oral tablets. Worth noting: it's a compounded medication and has not been FDA-approved for safety or efficacy.
A new nasal spray for erectile dysfunction called Roxus has officially launched in the United States, available by prescription through Mavrox, a men's health telemedicine platform. Developed by LTR Pharma Limited, Roxus delivers vardenafil — the same active ingredient found in common ED tablets — via a nasal formulation already available in Australia under the name Spontan for the past two years.
The big selling point? Speed. A peer-reviewed phase 1 study found that nasal vardenafil reaches peak blood levels in a median of just 10 minutes, compared to 45–60 minutes for the tablet form. Men aged 65 and older achieved peak levels just as quickly as younger men, and the spray hits those levels at roughly one-quarter of the standard tablet dose.
By the Numbers:
Why it matters: Faster onset could meaningfully improve outcomes for ED patients who find the long wait time of oral medications inconvenient. However, Roxus is a compounded medication — meaning it has not been reviewed or approved by the FDA for safety or effectiveness — a key consideration for both patients and prescribers.
